A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

NCT06155084 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: HP518 - Dose Escalation
DRUG: HP518 - Dose Escalation
DRUG: HP518 -Dose Expansion

Sponsor

Hinova Pharmaceuticals Inc.